Related Experiment Video

Updated: Aug 18, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Functional significance of protein kinase C in human T-cell activation: a new therapeutic class?

T J Hallam1

  • 1Roche Research Centre, Welwyn Garden City, Herts, U.K.

Clinical and Experimental Rheumatology
|March 1, 1993
PubMed

Insights

Protein kinase C (PKC) activation is vital for T-cell activation. Selective PKC inhibitors effectively prevent T-cell driven inflammatory responses in vivo, confirming PKC's crucial role.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • T-cell activation is critical for adaptive immunity.
  • Protein kinase C (PKC) activation is hypothesized to be essential for T-cell activation.
  • Existing evidence linking PKC to T-cell activation is largely circumstantial.

Purpose of the Study:

  • To investigate the necessity of PKC activation for T-cell activation.
  • To develop and utilize potent, selective, and cell-permeable PKC inhibitors.
  • To assess the in vivo efficacy of orally bioavailable PKC inhibitors in preventing T-cell mediated inflammation.

Main Methods:

  • Development of novel, potent, cell-permeable, and selective protein kinase C (PKC) inhibitors.
  • Utilizing these inhibitors to test the hypothesis of PKC's role in T-cell activation.
  • Evaluating the efficacy of orally bioavailable PKC inhibitors in preclinical models of chronic inflammatory diseases.

Main Results:

  • Demonstrated the crucial role of PKC in T-cell activation.
  • Confirmed that selective PKC inhibitors block T-cell activation.
  • Showed that orally bioavailable PKC inhibitors are effective in preventing T-cell driven chronic inflammatory responses in vivo.

Conclusions:

  • PKC activation is a necessary component of T-cell activation.
  • Selective and orally bioavailable PKC inhibitors represent a promising therapeutic strategy for T-cell mediated inflammatory conditions.
  • Targeting PKC offers a viable approach to modulate immune responses in inflammatory diseases.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: